Unnatural Nucleoside Analogs for Antisense Therapy

Natural Products in Medicinal Chemistry

Volumn , Issue , 2014, Pages 403-440

  Seth, Punit P ^a   Swayze, Eric E ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense therapy; C5 Methyl pyrimidines; Conformationally restricted nucleic acids; Phosphorothioate linkage

Indexed keywords

EID: 84926429679     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527676545.ch12     Document Type: Chapter

References (164)

1. Crick, F. (1970) Central dogma of molecular biology. Nature, 227, 561-563.
2. Green, R. and Noller, H.F. (1997) Ribosomes and translation. Annual Review of Biochemistry, 66, 679-716.
3. Gilbert, W. (1978) Why genes in pieces? Nature, 271, 501-1501.
4. Orgel, L.E. and Crick, F.H.C. (1980) Selfish DNA: the ultimate parasite. Nature, 284, 604-607.
5. Taft, R.J., Pheasant, M., and Mattick, J.S. (2007) The relationship between non-protein-coding DNA and eukaryotic complexity. BioEssays, 29, 288-299.
6. Mattick, J.S. (2011) The central role of RNA in human development and cognition. FEBS Letters, 585, 1600-1616.
7. Sharp, P.A. (2009) The centrality of RNA. Cell, 136, 577-580.
8. Clark, M.B., Amaral, P.P., Schlesinger, F. J., Dinger, M.E., Taft, R.J., Rinn, J.L., Ponting, C.P., Stadler, P.F., Morris, K.V., Morillon, A., Rozowsky, J.S., Gerstein, M. B., Wahlestedt, C., Hayashizaki, Y., Carninci, P., Gingeras, T.R., and Mattick, J. S. (2011) The reality of pervasive transcription. PLoS Biology, 9, e1000625; discussion e1001102.
9. Zamecnik, P.C. and Stephenson, M.L. (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proceedings of the National Academy of Sciences of the United States of America, 75, 280-284.
10. Bennett, C.F. and Swayze, E.E. (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annual Review of Pharmacology and Toxicology, 50, 259-293.
11. Houseley, J. and Tollervey, D. (2009) The many pathways of RNA degradation. Cell, 136, 763-776.
12. Wu, H., Lima, W.F., and Crooke, S.T. (1999) Properties of cloned and expressed human RNase H1. The Journal of Biological Chemistry, 274, 28270-28278.
13. 0-deoxy gaps as antisense inhibitors of gene expression. The Journal of Biological Chemistry, 268, 14514-14522.
14. Dykxhoorn, D.M., Novina, C.D., and Sharp, P.A. (2003) Killing the messenger: short RNAs that silence gene expression. Nature Reviews. Molecular Cell Biology, 4, 457-467.
15. Liu, J., Carmell, M.A., Rivas, F.V., Marsden, C.G., Thomson, J.M., Song, J.J., Hammond, S.M., Joshua-Tor, L., and Hannon, G.J. (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science, 305, 1437-1441.
16. Bartel, D.P. (2009) MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-233.
17. Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K.G., Tuschl, T., Manoharan, M., and Stoffel, M. (2005) Silencing of microRNAs in vivo with ántagomirs'. Nature, 43, 685-689.
18. Kole, R., Krainer, A.R., and Altman, S. (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nature Reviews. Drug Discovery, 11, 125-140.
19. Rigo, F., Hua, Y., Chun, S.J., Prakash, T.P., Krainer, A.R., and Bennett, C.F. (2012) Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing. Nature Chemical Biology, 8, 555-561.
20. Guttman, M. and Rinn, J.L. (2012) Modular regulatory principles of large non-coding RNAs. Nature, 482, 339-346.
21. Cooper, T.A. (2009) Neutralizing toxic RNA. Science, 325, 272-273.
22. Swayze, E.E. and Bhat, B. (2007) The medicinal chemistry of oligonucleotides, in Antisense Drug Technology: Principles, Strategies, and Applications, 2nd edn (ed. S. T. Crooke), CRC Press, Boca Raton, FL, pp. 143-182.
23. Jones, D. (2011) The long march of antisense. Nature Reviews. Drug Discovery, 10, 401-402.
24. Tavitian, B., Terrazzino, S., Kuhnast, B., Marzabal, S., Stettler, O., Dolle, F., Deverre, J.-R., Jobert, A., Hinnen, F., Bendriem, B., Crouzel, C., and DiGiamberardino, L. (1998) In vivo imaging of oligonucleotides with positron emission tomography. Nature Medicine, 4, 467-471.
25. Geary, R.S. (2009) Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opinion on Drug Metabolism and Toxicology, 5, 381-391.
26. IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN) (1983) Abbreviations and symbols for the description of conformations of polynucleotide chains. European Journal of Biochemistry, 131, 9-15.
27. Saenger, W. (1984) Principles of Nucleic Acid Structure, Springer, New York.
28. Altona, C. and Sundaralingam, M. (1972) Conformational analysis of the sugar ring in nucleosides and nucleotides. A new description using the concept of pseudorotation. Journal of the American Chemical Society, 94, 8205-8212.
29. Plavec, J., Tong, W., and Chattopadhyaya, J. (1993) How do the gauche and anomeric effects drive the pseudorotational equilibrium of the pentofuranose moiety of nucleosides? Journal of the American Chemical Society, 115, 9734-9746.
30. Thibaudeau, C., Plavec, J., Garg, N., Papchikhin, A., and Chattopadhyaya, J. (1994) How does the electronegativity of the substituent dictate the strength of the gauche effect? Journal of the American Chemical Society, 116, 4038-4043.
31. 0-gauche effect? Journal of the American Chemical Society, 116, 6558-6560.
32. 3/O nonbonding attractive interaction. The Journal of Physical Chemistry, 97, 1346-1350.
33. 0-hydroxyl group: crystal structures of DNA-RNA chimeric duplexes. Biochemistry, 32, 3221-3237.
34. 0)-adenosine hemihydrate. Conformational rigidity of the nucleotide unit and models for polynucleotide chain folding. Biochemistry, 11, 3112-3128.
35. Cantara, W.A., Crain, P.F., Rozenski, J., McCloskey, J.A., Harris, K.A., Zhang, X., Vendeix, F.A.P., Fabris, D., and Agris, P.F. (2011) The RNA modification database, RNAMDB: 2011 update. Nucleic Acids Research, 39, D195-D201.
36. Prakash, T.P. (2011) An overview of sugar-modified oligonucleotides for antisense therapeutics. Chemistry & Biodiversity, 8, 1616-1641.
37. 0-O-ribonucleic acid modifications. Biochemistry, 44, 9045-9057.
38. Shibahara, S., Mukai, S., Nishihara, T., Inoue, H., Ohtsuka, E., and Morisawa, H. (1987) Site-directed cleavage of RNA. Nucleic Acids Research, 15, 4403-4415.
39. Prakash, T.P., Allerson, C.R., Dande, P., Vickers, T.A., Sioufi, N., Jarres, R., Baker, B.F., Swayze, E.E., Griffey, R.H., and Bhat, B. (2005) Positional effect of chemical modifications on short interference RNA activity in mammalian cells. Journal of Medicinal Chemistry, 48, 4247-4253.
40. Jackson, A.L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J.M., Lim, L., Karpilow, J., Nichols, K., Marshall, W., Khvorova, A., and Linsley, P. S. (2006) Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA, 12, 1197-1205.
41. 0-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. Journal of Medicinal Chemistry, 48, 901-904.
42. Lima, W.F., Prakash, T.P., Murray, H.M., Kinberger, G.A., Li, W., Chappell, A.E., Li, C.S., Murray, S.F., Gaus, H., Seth, P.P., Swayze, E.E., and Crooke, S.T. (2012) Single-stranded siRNAs activate RNAi in animals. Cell, 150, 883-894.
43. 0 -O-ethylene glycol substituted ribonucleosides. Nucleosides, Nucleotides and Nucleic Acids, 16, 917-926.
44. Martin, P. (1995) Ein neuer Zugang zu 2-O-Alkylribonucleosiden und Eigenschaften deren Oligonucleotide. Helvetica Chimica Acta, 78, 486-504.
45. 0-O-(2-methoxyethyl)-RNA. Nature Structural & Molecular Biology, 6, 535-539.
46. Eckstein, F. (2000) Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense and Nucleic Acid Drug Development, 10, 117-121.
47. Akdim, F., Visser, M.E., Tribble, D.L., Baker, B.F., Stroes, E.S., Yu, R., Flaim, J.D., Su, J., Stein, E.A., and Kastelein, J.J. (2010) Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. The American Journal of Cardiology, 105, 1413-1419.
48. Raal, F.J., Santos, R.D., Blom, D.J., Marais, A.D., Charng, M.J., Cromwell, W.C., Lachmann, R.H., Gaudet, D., Tan, J.L., Chasan-Taber, S., Tribble, D.L., Flaim, J.D., and Crooke, S.T. (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet, 375, 998-1006.
49. Akdim, F., Stroes, E.S., Sijbrands, E.J., Tribble, D.L., Trip, M.D., Jukema, J.W., Flaim, J.D., Su, J., Yu, R., Baker, B.F., Wedel, M.K., and Kastelein, J.J. (2010) Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. Journal of the American College of Cardiology, 55, 1611-1618.
50. Hua, Y., Sahashi, K., Rigo, F., Hung, G., Horev, G., Bennett, C.F., and Krainer, A.R. (2011) Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature, 478, 123-126.
51. Passini, M.A., Bu, J., Richards, A.M., Kinnecom, C., Sardi, S.P., Stanek, L.M., Hua, Y., Rigo, F., Matson, J., Hung, G., Kaye, E.M., Shihabuddin, L.S., Krainer, A. R., Bennett, C.F., and Cheng, S.H. (2011) Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Science Translational Medicine, 3, 72ra18.
52. Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M.A., Bennett, C.F., and Krainer, A.R. (2010) Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes & Development, 24, 1634-1644.
53. 0 -modified hammerhead ribozymes. Science, 253, 314-317.
54. 0 -fluoro-modified siRNAs. Angewandte Chemie -International Edition, 50, 2284-2288.
55. Davis, S., Lollo, B., Freier, S., and Esau, C. (2006) Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Research, 34, 2294-2304.
56. Esau, C., Davis, S., Murray, S.F., Yu, X.X., Pandey, S.K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., Subramaniam, A., Propp, S., Lollo, B.A., Freier, S., Bennett, C.F., Bhanot, S., and Monia, B.P. (2006) mir-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metabolism, 3, 87-98.
57. Davis, S., Propp, S., Freier, S.M., Jones, L. E., Serra, M.J., Kinberger, G., Bhat, B., Swayze, E.E., Bennett, C.F., and Esau, C. (2009) Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Research, 37, 70-77.
58. Ng, E.W., Shima, D.T., Calias, P., Cunningham, E.T., Jr., Guyer, D.R., and Adamis, A.P. (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nature Reviews. Drug Discovery, 5, 123-132.
59. Hagmann, W.K. (2008) The many roles for fluorine in medicinal chemistry. Journal of Medicinal Chemistry, 51, 4359-4369.
60. Purser, S., Moore, P.R., Swallow, S., and Gouverneur, V. (2008) Fluorine in medicinal chemistry. Chemical Society Reviews, 37, 320-330.
61. 0 -fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. Journal of Medicinal Chemistry, 36, 831-841.
62. Griffey, R.H., Lesnik, E., Freier, S., Sanghvi, Y.S., Teng, K., Kawasaki, A., Guinosso, G., Wheeler, P., Mohan, V., and Cook, P.D. (1994) New twists on nucleic acids: structural properties of modified nucleosides incorporated into oligonucleotides, in Carbohydrate Modifications in Antisense Research (eds Y.S. Sanghvi and P.D. Cook), Oxford University Press, Washington, DC, pp. 212-224.
63. 0 -fluoro-modified RNA. Nucleic Acids Research, 39 (8), 3482-3895.
64. 0-C-branched oligodeoxynucleotides and the development of locked nucleic acid (LNA). Accounts of Chemical Research, 32, 301-310.
65. Imanishi, T. and Obika, S. (2002) BNAs: novel nucleic acid analogs with a bridged sugar moiety. Chemical Communications, 1653-1659.
66. Koshkin, A.A., Nielsen, P., Meldgaard, M., Rajwanshi, V.K., Singh, S.K., and Wengel, J. (1998) LNA (locked nucleic acid): an RNA mimic forming exceedingly stable LNA:LNA duplexes. Journal of the American Chemical Society, 120, 13252-13253.
67. Koshkin, A.A., Singh, S.K., Nielsen, P., Rajwanshi, V.K., Kumar, R., Meldgaard, M., Olsen, C.E., and Wengel, J. (1998) LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerization, and unprecedented nucleic acid recognition. Tetrahedron, 54, 3607-3630.
68. 0-endo sugar puckering. Tetrahedron Letters, 38, 8735-8738.
69. 0-C-methyleneribonucleosides. Tetrahedron Letters, 39, 5401-5404.
70. Eichert, A., Behling, K., Betzel, C., Erdmann, V.A., Furste, J.P., and Forster, C. (2010) The crystal structure of an 'All Locked' nucleic acid duplex. Nucleic Acids Research, 38, 6729-6736.
71. 0 -thio-LNA. Bioorganic & Medicinal Chemistry Letters, 8, 2219-2222.
72. 0-thio-LNA monomeric nucleosides. The Journal of Organic Chemistry, 63, 6078-6079.
73. 0-carbocyclic ribo-thymidines: synthesis, structure, and biochemical studies. Journal of the American Chemical Society, 129, 8362-8379.
74. Veedu, R.N. and Wengel, J. (2010) Locked nucleic acids: promising nucleic acid analogs for therapeutic applications. Chemistry & Biodiversity, 7, 536-542.
75. Swayze, E.E., Siwkowski, A.M., Wancewicz, E.V., Migawa, M.T., Wyrzykiewicz, T.K., Hung, G., Monia, B. P., and Bennett, C.F. (2007) Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Research, 35, 687-700.
76. 0 conformationally restricted nucleoside analogues show improved potency without increased toxicity in animals. Journal of Medicinal Chemistry, 52, 10-13.
77. 0 O-ethyl nucleic acid analogues. The Journal of Organic Chemistry, 75, 1569-1581.
78. 0 -O-ethyl (cEt) modified DNAs. Chemical Communications, 48, 8195-8197.
79. 0 -methyl group modulates the biophysical and biological properties of locked nucleic acid (LNA) oligonucleotides. Journal of Medicinal Chemistry, 53, 8309-8318.
80. Zhou, C. and Chattopadhyaya, J. (2012) Intramolecular free-radical cyclization reactions on pentose sugars for the synthesis of carba-LNA and carba-ENA and the application of their modified oligonucleotides as potential RNA targeted therapeutics. Chemical Reviews, 112, 3808-3832.
81. 0 -oxygen atom in LNA. Journal of the American Chemical Society, 132, 14942-14950.
82. 0 -C-bridged bicyclonucleosides. Tetrahedron, 55, 7707-7724.
83. 0-deoxynucleosides. Bioorganic & Medicinal Chemistry Letters, 9, 1147-1150.
84. 0 -carbocyclic-LNAs and-ENAs leads to significant modulation of antisense properties. The Journal of Organic Chemistry, 74, 118-134.
85. Kumar, S., Hansen, M.H., Albaek, N., Steffansen, S.I., Petersen, M., and Nielsen, P. (2009) Synthesis of functionalized carbocyclic locked nucleic acid analogues by ring-closing diene and enyne metathesis and their influence on nucleic acid stability and structure. The Journal of Organic Chemistry, 74, 6756-6769.
86. 0-linkages: synthesis by ring-closing metathesis and influence on nucleic acid duplex stability and structure. The Journal of Organic Chemistry, 71, 7731-7740.
87. 0-C-ethylene-bridged thymidine (aza-ENA-T): synthesis, structure, physical, and biochemical studies of aza-ENA-T-modified oligonucleotides. Journal of the American Chemical Society, 128, 15173-15187.
88. 0 -BNANC: a bridged nucleic acid analogue. Journal of the American Chemical Society, 130, 4886-4896.
89. 0-C-aminomethylene bridged nucleoside analogues show improved potency in animal models. Journal of Medicinal Chemistry, 53, 1636-1650.
90. Rajwanshi, V.K., Hakansson, A.E., Sorensen, M.D., Pitsch, S., Singh, S.K., Kumar, R., Nielsen, P., and Wengel, J. (2000) The eight stereoisomers of LNA (locked nucleic acid): a remarkable family of strong RNA binding molecules. Angewandte Chemie -International Edition, 39, 1656-1659.
91. Sorensen, M.D., Kvaerno, L., Bryld, T., Hakansson, A.E., Verbeure, B., Gaubert, G., Herdewijn, P., and Wengel, J. (2002) Alpha-L-ribo-configured locked nucleic acid (alpha-L-LNA): synthesis and properties. Journal of the American Chemical Society, 124, 2164-2176.
92. Nielsen, J.T., Stein, P.C., and Petersen, M. (2003) NMR structure of an alpha-L-LNA: RNA hybrid: structural implications for RNase H recognition. Nucleic Acids Research, 31, 5858-5867.
93. Bondensgaard, K., Petersen, M., Singh, S. K., Rajwanshi, V.K., Kumar, R., Wengel, J., and Jacobsen, J.P. (2000) Structural studies of LNA:RNA duplexes by NMR: conformations and implications for RNase H activity. Chemistry -A European Journal, 6, 2687-2695.
94. Ostergaard, M.E. and Hrdlicka, P.J. (2011) Pyrene-functionalized oligonucleotides and locked nucleic acids (LNAs): tools for fundamental research, diagnostics, and nanotechnology. Chemical Society Reviews, 40, 5771-5778.
95. 0-oxygen with an exocyclic methylene group reverses the stabilization effects of alpha-L-LNA. Bioorganic & Medicinal Chemistry Letters, 21, 588-591.
96. Li, Q., Yuan, F., Zhou, C., Plashkevych, O., and Chattopadhyaya, J. (2010) Free-radical ring closure to conformationally locked alpha-L-carba-LNAs and synthesis of their oligos: nuclease stability, target RNA specificity, and elicitation of RNase H. The Journal of Organic Chemistry, 75, 6122-6140.
97. 0-Me-alpha-L-LNA modified oligonucleotides. Bioorganic & Medicinal Chemistry Letters, 21, 1122-1125.
98. 0 -Me-alpha-L-LNA -substitution in the minor groove of alpha-L-LNA duplexes. Bioorganic & Medicinal Chemistry Letters, 21, 4690-4694.
99. 0-position are different in alpha-L-LNA as compared to beta-D-LNA. Bioorganic & Medicinal Chemistry Letters, 22, 296-299.
100. Seth, P.P., Jazayeri, A., Yu, J., Allerson, C. R., Bhat, B., and Swayze, E.E. (2012) Structure activity relationships of alpha-L-LNA modified phosphorothioate gapmer antisense oligonucleotides in animals. Molecular Therapy -Nucleic Acids, 1, e47.
101. Herdewijn, P. (2010) Nucleic acids with a six-membered 'carbohydrate' mimic in the backbone. Chemistry & Biodiversity, 7, 1-59.
102. Maier, T., Przylas, I., Strater, N., Herdewijn, P., and Saenger, W. (2005) Reinforced HNA backbone hydration in the crystal structure of a decameric HNA/ RNA hybrid. Journal of the American Chemical Society, 127, 2937-2943.
103. Lescrinier, E., Esnouf, R., Schraml, J., Busson, R., Heus, H., Hilbers, C., and Herdewijn, P. (2000) Solution structure of a HNA-RNA hybrid. Chemistry & Biology, 7, 719-731.
104. Allart, B., Khan, K., Rosemeyer, H., Schepers, G., Hendrix, C., Rothenbacher, K., Seela, F., Aerschot, A.V., and Herdewijn, P. (1999) D-Altritol nucleic acids (ANA): hybridisation properties, stability, and initial structural analysis. Chemistry -A European Journal, 5, 2424-2431.
105. 0-fluoro hexitol nucleic acid (FHNA and Ara-FHNA) modified oligonucleotides. Journal of the American Chemical Society, 133, 16642-16649.
106. Anzahaee, M.Y., Watts, J.K., Alla, N.R., Nicholson, A.W., and Damha, M.J. (2011) Energetically important C-H-F-C pseudohydrogen bonding in water: evidence and application to rational design of oligonucleotides with high binding affinity. Journal of the American Chemical Society, 133, 728-731.
107. Leumann, C.J. (2002) DNA analogues: from supramolecular principles to biological properties. Bioorganic & Medicinal Chemistry, 10, 841-854.
108. 0-ethano-b-D-ribofuranosyl]adenosine and -thymine. Helvetica Chimica Acta, 77, 716-744.
109. 0-ethano-ab-D-ribonucleosides (bicyclonucleosides). Helvetica Chimica Acta, 76, 481-510.
110. Strickland, R.G., Miller, W.C., Volpicelli, N. A., Gaeke, R.F., Wilson, I.D., Kirsner, J.B., and Williams, R.C., Jr. (1977) Lymphocytotoxic antibodies in patients with inflammatory bowel disease and their spouses -evidence for a transmissible agent. Clinical and Experimental Immunology, 30, 188-192.
111. Bolli, M., Trafelet, H.U., and Leumann, C. (1996) Watson-Crick base-pairing properties of bicyclo-DNA. Nucleic Acids Research, 24, 4660-4667.
112. 0) ethylene bridges. Journal of the American Chemical Society, 115, 5855-5856.
113. Pallan, P.S., Ittig, D., Heroux, A., Wawrzak, Z., Leumann, C.J., and Egli, M. (2008) Crystal structure of tricyclo-DNA: an unusual compensatory change of two adjacent backbone torsion angles. Chemical Communications, 883-885.
114. 0)-a-functionalized bicyclo-DNA. Bioorganic & Medicinal Chemistry, 18, 7786-7793.
115. 0). Heterocycles, 82, 775-790.
116. Lietard, J., Ittig, D., and Leumann, C.J. (2011) Synthesis, binding and cellular uptake properties of oligodeoxynucleotides containing cationic bicyclo-thymidine residues. Bioorganic and Medicinal Chemistry, 19, 5869-5875.
117. Haziri, A.I. and Leumann, C.J. (2012) Synthesis and pairing properties of oligodeoxynucleotides containing bicyclo-RNA and bicyclo-ANA modifications. The Journal of Organic Chemistry, 77, 5861-5869.
118. Ahn, D.R., Egger, A., Lehmann, C., Pitsch, S., and Leumann, C.J. (2002) Bicyclo[3.2.1] amide-DNA: a chiral, nonchiroselective base-pairing system. Chemistry, 8, 5312-5322.
119. 0 -amino-bicyclo-thymidine). Helvetica Chimica Acta, 82, 1813-1828.
120. 0-epi-bicyclodeoxynucleosides). Helvetica Chimica Acta, 79, 1129-1146.
121. 4,3-DNA. European Journal of Organic Chemistry, 2009, 1153-1162.
122. Renneberg, D., Bouliong, E., Reber, U., Schumperli, D., and Leumann, C.J. (2002) Antisense properties of tricyclo-DNA. Nucleic Acids Research, 30, 2751-2757.
123. Steffens, R. and Leumann, C.J. (1999) Synthesis and thermodynamic and biophysical properties of tricyclo-DNA. Journal of the American Chemical Society, 121, 3249-3255.
124. Steffens, R. and Leumann, C.J. (1997) Tricyclo-DNA: a phosphodiester-backbone based DNA analog exhibiting strong complementary base-pairing properties. Journal of the American Chemical Society, 119, 11548-11549.
125. Renneberg, D. and Leumann, C.J. (2002) Watson-Crick base-pairing properties of tricyclo-DNA. Journal of the American Chemical Society, 124, 5993-6002.
126. 0-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues -a comparative study of oligonucleotide length, design and chemistry. Nucleic Acids Research, 40, 6135-6143.
127. LeClezio, I., Dupouy, C., Lavedan, P., and Escudier, J.-M. (2007) Synthesis and structure of an a,b-D-CNA featuring a noncanonical a/b torsion angle combination within a tetranucleotide. European Journal of Organic Chemistry, 3894-3900.
128. Dupouy, C., Le, C.I., Lavedan, P., Gornitzka, H., Escudier, J.-M., and Vigroux, A. (2006) Diastereoselective synthesis of conformationally restricted dinucleotides featuring canonical and non-canonical a/b torsion angle combinations (a,b-D-CNA). European Journal of Organic Chemistry, 5515-5525.
129. Dupouy, C., Iche-Tarrat, N., Durrieu, M.P., Rodriguez, F., Escudier, J.M., and Vigroux, A. (2006) Watson-Crick base-pairing properties of nucleic acid analogues with stereocontrolled alpha and beta torsion angles (alpha,beta-D-CNAs). Angewandte Chemie -International Edition, 45, 3623-3627.
130. LeClezio, I., Escudier, J.-M., and Vigroux, A. (2003) Diastereoselective synthesis of a conformationally restricted dinucleotide with predefined a and b torsional angles for the construction of a,b-constrained nucleic acids (a,b-CNA). Organic Letters, 5, 161-164.
131. Dupouy, C., Millard, P., Boissonnet, A., and Escudier, J.-M. (2010) a,b-D-CNA preorganization of unpaired loop moiety stabilizes DNA hairpin. Chemical Communications, 46, 5142-5144.
132. Martínez, O., Ecochard, V., Mahéo, S., Gross, G., Bodin, P., Teissié, J., Escudier, J.-M., and Paquereau, L. (2011) a,b-D-Constrained nucleic acids are strong terminators of thermostable DNA polymerases in polymerase chain reaction. PLoS One, 6, e25510.
133. Catana, D.-A., Maturano, M., Payrastre, C., Lavedan, P., Tarrat, N., and Escudier, J.-M. (2011) Synthesis of phostone-constrained nucleic acid (P-CNA) dinucleotides through intramolecular Arbuzov's reaction. European Journal of Organic Chemistry, 2011, 6857-6863.
134. LeClezio, I., Vigroux, A., and Escudier, J.-M. (2007) Diastereoselective and regioselective synthesis of conformationally restricted thio-dioxa- and oxo-oxathiaphosphorinane dinucleotides featuring noncanonical a/b torsion angle combinations (a,b-CNAs). European Journal of Organic Chemistry, 1935-1941.
135. Dupouy, C., Lavedan, P., and Escudier, J.-M. (2007) Synthesis and structure of dinucleotides featuring canonical and non-canonical A-type duplex a, b and d torsion angle combinations (LNA/a,b-D-CNA). European Journal of Organic Chemistry, 5256-5264.
136. Dupouy, C., Lavedan, P., and Escudier, J.-M. (2007) Synthesis of spiro e,f-D-CNA in xylo configuration featuring noncanonical d/e/f torsion angle combination. Tetrahedron, 63, 11235-11243.
137. 2,e,f-D-CNA). European Journal of Organic Chemistry, 1285-1294.
138. Eckstein, F. (1967) A dinucleoside phosphorothioate. Tetrahedron Letters, 8, 1157-1160.
139. Wang, L., Chen, S., Xu, T., Taghizadeh, K., Wishnok, J.S., Zhou, X., You, D., Deng, Z., and Dedon, P.C. (2007) Phosphorothioation of DNA in bacteria by dnd genes. Nature Chemical Biology, 3, 709-710.
140. Eckstein, F. (2007) Phosphorothioation of DNA in bacteria. Nature Chemical Biology, 3, 689-690.
141. Xie, X., Liang, J., Pu, T., Xu, F., Yao, F., Yang, Y., Zhao, Y.L., You, D., Zhou, X., Deng, Z., and Wang, Z. (2012) Phosphorothioate DNA as an antioxidant in bacteria. Nucleic Acids Research, 40, 9115-9124.
142. Agrawal, S., Goodchild, J., Civeira, M.P., Thornton, A.H., Sarin, P.S., and Zamecnik, P.C. (1988) Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proceedings of the National Academy of Sciences of the United States of America, 85, 7079-7083.
143. Reynolds, M.A., Hogrefe, R.I., Jaeger, J.A., Schwartz, D.A., Riley, T.A., Marvin, W.B., Daily, W.J., Vaghefi, M.M., Beck, T.A., Knowles, S.K., Klem, R.E., and Arnold, L. J., Jr. (1996) Synthesis and thermodynamics of oligonucleotides containing chirally pure R(P) methylphosphonate linkages. Nucleic Acids Research, 24, 4584-4591.
144. Iversen, P.L. (2001) Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Current Opinion in Molecular Therapeutics, 3, 235-238.
145. Wu, B., Moulton, H.M., Iversen, P.L., Jiang, J., Li, J., Li, J., Spurney, C.F., Sali, A., Guerron, A.D., Nagaraju, K., Doran, T., Lu, P., Xiao, X., and Lu, Q.L. (2008) Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proceedings of the National Academy of Sciences of the United States of America, 105, 14814-14819.
146. Metcalf, W.W., Griffin, B.M., Cicchillo, R. M., Gao, J., Janga, S.C., Cooke, H.A., Circello, B.T., Evans, B.S., Martens-Habbena, W., Stahl, D.A., and van derDonk, W.A. (2012) Synthesis of methylphosphonic acid by marine microbes: a source for methane in the aerobic ocean. Science, 337, 1104-1107.
147. Benimetskaya, L., Tonkinson, J.L., Koziolkiewicz, M., Karwowski, B., Guga, P., Zeltser, R., Stec, W., and Stein, C.A. (1995) Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent. Nucleic Acids Research, 23, 4239-4245.
148. Stein, C.A., Hansen, J.B., Lai, J., Wu, S., Voskresenskiy, A., Hog, A., Worm, J., Hedtjarn, M., Souleimanian, N., Miller, P., Soifer, H.S., Castanotto, D., Benimetskaya, L., Orum, H., and Koch, T. (2010) Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Research, 38, e3.
149. Koller, E., Vincent, T.M., Chappell, A., De, S., Manoharan, M., and Bennett, C.F. (2011) Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Research, 39, 4795-4807.
150. Bennett, C.F., Swayze, E., Geary, R., Henry, S., Tillman, L., and Hardee, G. (2009) Antisense oligonucleotide-based therapeutics, in Gene and Cell Therapy, 3rd edn (ed. N. Smyth Templeton), CRC Press, Boca Raton, FL, pp. 497-522.
151. Henry, S.P., Geary, R.S., Yu, R., and Levin, A.A. (2001) Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Current Opinion in Investigational Drugs, 2, 1444-1449.
152. 0 O-methoxyethyl chimeric antisense inhibitors in animals and man, in Antisense Drug Technology: Principles, Strategies and Applications, 2nd edn (ed. S.T. Crooke), CRC Press, Boca Raton, FL, pp. 327-364.
153. Singal, R. and Ginder, G.D. (1999) DNA methylation. Blood, 93, 4059-4070.
154. Motorin, Y., Lyko, F., and Helm, M. (2010) 5-Methylcytosine in RNA: detection, enzymatic formation and biological functions. Nucleic Acids Research, 38, 1415-1430.
155. Krieg, A.M. (1999) Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochimica et Biophysica Acta, 1489, 107-116.
156. Krieg, A.M. (2002) CPG motifs in bacterial DNA and their immune effects. Annual Review of Immunology, 20, 709-760.
157. Wagner, R.W., Matteucci, M.D., Lewis, J. G., Gutierrez, A.J., Moulds, C., and Froehler, B.C. (1993) Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science, 260, 1510-1513.
158. Wagner, R.W., Matteucci, M.D., Grant, D., Huang, T., and Froehler, B.C. (1996) Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nature Biotechnology, 14, 840-844.
159. Gutierrez, A.J., Matteucci, M.D., Grant, D., Matsumura, S., Wagner, R.W., and Froehler, B.C. (1997) Antisense gene inhibition by C-5-substituted deoxyuridine-containing oligodeoxynucleotides. Biochemistry, 36, 743-748.
160. 0-deoxyuridine analogs. Synthesis and incorporation into high-affinity oligonucleotides. Journal of the American Chemical Society, 116, 5540-5544.
161. 0-deoxycytidine analogs: syntheses and incorporation into oligodeoxynucleotides which have enhanced binding to complementary RNA. Journal of the American Chemical Society, 117, 3873-3874.
162. Wilds, C.J., Maier, M.A., Tereshko, V., Manoharan, M., and Egli, M. (2002) Direct observation of a cytosine analogue that forms five hydrogen bonds to guanosine: guanidino G-clamp. Angewandte Chemie -International Edition, 41, 115-117.
163. Flanagan, W.M., Wolf, J.J., Olson, P., Grant, D., Lin, K.-Y., Wagner, R.W., and Matteucci, M.D. (1999) A cytosine analog that confers enhanced potency to antisense oligonucleotides. Proceedings of the National Academy of Sciences of the United States of America, 96, 3513-3518.
164. Lin, K.-Y. and Matteucci, M.D. (1998) A cytosine analog capable of clamp-like binding to a guanine in helical nucleic acids. Journal of the American Chemical Society, 120, 8531-8532.